Table 5.
Analysis of potential DDIs in accordance with the Food and Drug Administration recommendations. Critical interactions exceeding the cutoff of R ≥ 1.1 are highlighted in bold
| Perpetrator |
|||||||||
|---|---|---|---|---|---|---|---|---|---|
| Fenoterol | Sumatriptan | Ipratropium | Trospium | Metformin | Quinidine | Verapamil | Trimethoprim | ||
| Victim drug | Fenoterol | 1.00 | 1.00 | 1.00 | 1.00 | 1.17 | 1.18 | 1.19 | |
| Salbutamol | 1.00 | 1.00 | 1.00 | 1.01 | 1.00 | 1.45 | 1.53 | 1.23 | |
| Sumatriptan | 1.00 | 1.00 | 1.00 | 1.01 | 1.11 | 1.09 | 1.71 | ||
| Zolmitriptan | 1.00 | 1.00 | 1.00 | 1.01 | 1.00 | 1.32 | 1.60 | 1.24 | |
| Ipratropium | 1.00 | 1.01 | 1.01 | 1.01 | 1.10 | 1.09 | 1.79 | ||
| Trospium | 1.00 | 1.01 | 1.00 | 1.00 | 1.15 | 1.13 | 1.46 | ||
| Methylnaltrexone | 1.00 | 1.00 | 1.00 | 1.01 | 1.01 | 1.32 | 1.29 | 1.45 | |
| Metformin | 1.00 | 1.00 | 1.00 | 1.01 | 1.25 | 1.30 | 1.20 | ||
DDI, drug-drug interaction; R, drug drug interaction risk.